KB-1134-01

Zolbetuximab

Background

Zolbetuximab, also named MAb362, is a novel chimeric IgG1 antibody highly specific for claudin 18.2. It is produced in Chinese Hamster Ovary (CHO) cells by standard recombinant expression technology. It binds to claudin 18.2 on the tumor cell surface to stimulate cellular and soluble immune effectors that activate antibody-dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). It can also induce apoptosis and inhibit cell proliferation.

Specifications

Catalog Number:
KB-1134-01
Cell Line Name:
Zolbetuximab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
18.2
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.Micke, Patrick, Johanna Sofia Margareta Mattsson, Karolina Edlund, Miriam Lohr, Karin Jirström, Anders Berglund, Johan Botling, et al. 2014. “Aberrantly Activated Claudin 6 and 18.2 as Potential Therapy Targets in Non-Small-Cell Lung Cancer.” International Journal of Cancer 135 (9): 2206–14. doi:10.1002/ijc.28857. 2.Singh, Prabhsimranjot, Sudhamshi Toom, and Yiwu Huang. 2017. “Anti-Claudin 18.2 Antibody as New Targeted Therapy for Advanced Gastric Cancer,” May. Journal of Hematology & Oncology, 1–5. doi:10.1186/s13045-017- 0473-4. 3.Sahin, U, M Koslowski, K Dhaene, D Usener, G Brandenburg, G Seitz, C Huber, and O Tureci. 2008. “Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development.” Clinical Cancer Research 14 (23): 7624–34. doi:10.1158/1078-0432.CCR-08-1547.
Please enable JavaScript in your browser to complete this form.